primary lung cancer (operable case)
Conditions
Interventions
In patients, intra-venous injection of alpha-GalactosylCeramide pulsed DCs is performed at 1week before operation. Within 3 months after operation he is re-entried, and alpha-GalactosylCeramide pulsed
Sponsors
Department of Thoracic Surgery, Graduate School of Medicine, Chiba University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients between 20 and 80 years of age, with a histologic or cytologic diagnosis of non–small cell lung cancer for which operation is planned. 2. Clinical stage is IIB or IIIA. 3. Performance status of 0, 1, or 2 4. Normal or near normal renal, hepatic, and hematopoietic function 5. NKT cells are detected at least 10 cells in 1 mL of peripheral blood.
Exclusion criteria
Exclusion criteria: 1. Patients who have been treated with surgery or chemotherapy or radiotherapy received for at least 4 weeks before enrollment. 2. Histology is large cell neuroendocrine carcinoma. 3. The exclusion criteria were a positive response to HIV, hepatitis C virus, or human T-cell lymphotrophic virus antibodies; positive for hepatitis B antigen; the presence of active inflammatory disease or active autoimmune disease; a history of hepatitis; pregnancy or lactation; concurrent corticosteroid therapy; and evidence for another active malignant neoplasm. The histologic type, tumor-node-metastasis classification, and the antitumor effect of treatment were classified according to the general rules for clinical and pathologic recording of lung cancer as described by the Japan Lung Cancer Society.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunological response | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety, Clinical response | — |
Countries
Japan
Outcome results
None listed